Description
RP-001 is an experimental therapeutic compound currently in early-phase clinical development for advanced malignancies including colorectal cancer. Based on its inclusion in tumor-agnostic trials, this agent appears to target a molecular pathway or mechanism that is relevant across multiple cancer types rather than being specific to colorectal cancer biology. The drug is being evaluated in a Phase 1/2a dose-escalation and expansion study to determine its safety profile, maximum tolerated dose, and preliminary efficacy signals in patients with advanced solid tumors.
Mechanism of Action
The specific molecular mechanism of action for RP-001 has not been publicly disclosed in available clinical trial documentation. Given its tumor-agnostic application, the compound likely targets a fundamental cellular process or pathway that is dysregulated across multiple cancer types, such as DNA repair mechanisms, cell cycle checkpoints, or metabolic pathways essential for tumor cell survival and proliferation.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Other Medications |
 Status | Experimental |
| Clinical Trials | 1 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.